Jan H M Schellens

Jan H M Schellens

UNVERIFIED PROFILE

Are you Jan H M Schellens?   Register this Author

Register author
Jan H M Schellens

Jan H M Schellens

Publications by authors named "Jan H M Schellens"

Are you Jan H M Schellens?   Register this Author

100Publications

2918Reads

36Profile Views

Bioanalytical LC-MS/MS validation of therapeutic drug monitoring assays in oncology.

Biomed Chromatogr 2020 Jan 27;34(1):e4623. Epub 2019 Nov 27.

Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/bmc.4623DOI Listing
January 2020

Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases.

Neurology 2020 Jan 6. Epub 2020 Jan 6.

From the Division of Pharmacology (M.T.J.v.B., D.P., B.M.K., J.H.B., J.H.M.S.), Clinical Pharmacology (M.T.J.v.B., B.M.K., J.H.B., J.H.M.S), Division of Pathology (M.B.), Department of Biometrics (K.S.), Department of Laboratory Medicine (D.T.C.L., D.v.d.B.), and Department of Neuro-oncology (D.B.), Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam; and Science Faculty (J.H.B., J.H.M.S), Pharmaceutical Sciences, Division of Pharmaco-epidemiology and Clinical Pharmacology, Utrecht University, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000008751DOI Listing
January 2020

Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.

CPT Pharmacometrics Syst Pharmacol 2019 Dec 20;8(12):940-950. Epub 2019 Nov 20.

Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/psp4.12474DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930859PMC
December 2019

Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma.

J Pharm Biomed Anal 2019 Dec 27;181:113073. Epub 2019 Dec 27.

Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpba.2019.113073DOI Listing
December 2019

Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD-1 Expression Levels and PD-1 Receptor Occupancy by Nivolumab and Pembrolizumab.

Cytometry A 2019 Oct 12;95(10):1053-1065. Epub 2019 Aug 12.

Division of Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.a.23873DOI Listing
October 2019

Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer.

N Engl J Med 2019 10 30;381(17):1632-1643. Epub 2019 Sep 30.

From the University of Texas M.D. Anderson Cancer Center, Houston (S.K., V.M.); West Cancer Center and Research Institute, OneOncology, Germantown, TN (A. Grothey); Memorial Sloan Kettering Cancer Center, New York (R.Y., A.K.); University Hospital Gasthuisberg and University of Leuven, Leuven, Belgium (E.V.C., J. Dekervel); the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (J. Desai, C.G.); National Cancer Center Hospital East, Kashiwa, Japan (T.Y.); Hammersmith Hospital, Division of Cancer, Imperial College London (H.W.), and the Sarah Cannon Research Institute and University College London Cancer Institute (H.-T.A.), London, and the Christie NHS Foundation Trust/National Institute for Health Research Manchester Biomedical Research Centre, Manchester (M.B.) - all in the United Kingdom; the University of Campania Luigi Vanvitelli, Naples (F.C.), and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua (F.L., S.L.) - both in Italy; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (Y.S.H., T.-W.K.); the Netherlands Cancer Institute, Amsterdam (N.S., J.H.M.S.); Oslo University Hospital, Oslo (T.K.G.); Hospital Gregorio Marañón, Madrid (P.G.-A., A.C.F.), and Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, UVic, IOB-Quiron, Barcelona (E.E., J.T.) - both in Spain; Odense University Hospital, Odense, Denmark (P.P., L.S.T.); Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia (S.O.); and Array BioPharma, Boulder, CO (A. Gollerkeri, C.K., K.M., M.P., J.C.-B., L.A., V.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1908075DOI Listing
October 2019

A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development.

J Clin Pharmacol 2019 Oct 9. Epub 2019 Oct 9.

Department of Pharmacy & Pharmacology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.1532DOI Listing
October 2019

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis.

Front Cell Infect Microbiol 2018 1;8:181. Epub 2018 Jun 1.

Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek Hospital/the Netherlands Cancer Institute, Amsterdam, Netherlands.

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fcimb.2018.00181
Publisher Site
http://dx.doi.org/10.3389/fcimb.2018.00181DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992270PMC
June 2019

Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.

Int J Cancer 2019 05 4;144(9):2347-2354. Epub 2019 Jan 4.

Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32022DOI Listing
May 2019

Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.

Drugs Aging 2019 04;36(4):379-385

Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek, The Netherlands Cancer Institute and MC Slotervaart, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40266-019-00643-2DOI Listing
April 2019

Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology.

Clin Pharmacokinet 2019 03;58(3):299-308

Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40262-018-0683-0DOI Listing
March 2019

Impact of age on exposure to oral antiandrogen therapies in clinical practice.

Prostate Cancer Prostatic Dis 2019 03 2;22(1):168-175. Epub 2018 Oct 2.

Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41391-018-0096-z
Publisher Site
http://dx.doi.org/10.1038/s41391-018-0096-zDOI Listing
March 2019

Development, validation, and clinical application of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of total intracellular β-decitabine nucleotides and genomic DNA incorporated β-decitabine and 5-methyl-2'-deoxycytidine.

J Pharm Biomed Anal 2019 Feb 3;164:16-26. Epub 2018 Oct 3.

Department of Pharmacy & Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek and MC Slotervaart, Amsterdam, the Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Science Faculty, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Division of Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpba.2018.10.001DOI Listing
February 2019

Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid.

J Pharm Biomed Anal 2019 Feb 17;164:128-134. Epub 2018 Oct 17.

Division of Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, the Netherlands; Department of Clinical Pharmacology, NKI-AVL, Amsterdam, the Netherlands; Department of Pharmacy and Pharmacology, NKI-AVL, Amsterdam, the Netherlands; Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands; Division of Medical Oncology, NKI-AVL, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07317085183037
Publisher Site
http://dx.doi.org/10.1016/j.jpba.2018.10.025DOI Listing
February 2019

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? - Authors' reply.

Lancet Oncol 2019 Feb;20(2):e67

Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, 3584 CG Utrecht, Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30010-5DOI Listing
February 2019

Development and validation of a quantitative method for thymidine phosphorylase activity in peripheral blood mononuclear cells.

Nucleosides Nucleotides Nucleic Acids 2018 4;37(8):436-454. Epub 2018 Oct 4.

a Department of Clinical Pharmacology , The Netherlands Cancer Institute , Amsterdam , The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15257770.2018.1498270DOI Listing
January 2019

A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.

Eur J Cancer 2019 Jan 11;107:60-67. Epub 2018 Dec 11.

Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049183147
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2018.11.010DOI Listing
January 2019

Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study.

Pharm Res 2019 Jan 7;36(2):33. Epub 2019 Jan 7.

Department of Pharmacy &Pharmacology, Antoni van Leeuwenhoek - Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11095-018-2563-6DOI Listing
January 2019

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.

Invest New Drugs 2018 12 5;36(6):1006-1015. Epub 2018 May 5.

Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek - The Netherlands Cancer Institute and MC Slotervaart, Louwesweg 6, 1066, EC, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-018-0593-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244972PMC
December 2018

Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real-world cohort study: does age matter?

Br J Clin Pharmacol 2018 12 26;84(12):2770-2778. Epub 2018 Sep 26.

Department of Pharmacy & Pharmacology, Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bcp.13725
Publisher Site
http://dx.doi.org/10.1111/bcp.13725DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256014PMC
December 2018

Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

J Chromatogr B Analyt Technol Biomed Life Sci 2018 Dec 30;1102-1103:167-172. Epub 2018 Oct 30.

Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Universiteitsweg 99, 3584 CG Utrecht, the Netherlands; The Netherlands Cancer Institute, Department of Clinical Pharmacology, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; MC Slotervaart, Department of Pharmacy & Pharmacology, Louwesweg 6, 1066 EC Amsterdam, the Netherlands. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15700232183129
Publisher Site
http://dx.doi.org/10.1016/j.jchromb.2018.10.023DOI Listing
December 2018

Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates.

J Pharm Biomed Anal 2018 Nov 19;161:136-143. Epub 2018 Aug 19.

Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands; The Netherlands Cancer Institute, Department of Clinical Pharmacology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; MC Slotervaart, Department of Pharmacy & Pharmacology, Louwesweg 6, 1066 EC Amsterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpba.2018.08.038DOI Listing
November 2018

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.

Lancet Oncol 2018 11 19;19(11):1459-1467. Epub 2018 Oct 19.

Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183068
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30686-7DOI Listing
November 2018

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants.

Genes (Basel) 2018 Nov 28;9(12). Epub 2018 Nov 28.

Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/genes9120585DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316498PMC
November 2018

Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and C-Erlotinib PET.

J Nucl Med 2018 06 24;59(6):973-979. Epub 2017 Nov 24.

Department of Clinical Pharmacology and Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.117.195800DOI Listing
June 2018

Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.

J Pharmacokinet Pharmacodyn 2018 06 10;45(3):431-442. Epub 2018 Feb 10.

Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek - The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10928-018-9579-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953989PMC
June 2018

The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases.

Eur J Clin Pharmacol 2018 Jun 11;74(6):737-744. Epub 2018 Feb 11.

Department of Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00228-018-2426-4DOI Listing
June 2018

Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.

Br J Clin Pharmacol 2018 06 16;84(6):1279-1289. Epub 2018 Apr 16.

Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek Hospital - The Netherlands Cancer Institute and MC Slotervaart, Louwesweg, 6, 1066, EC, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.13557DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980516PMC
June 2018

Solubility and bioavailability improvement of pazopanib hydrochloride.

Int J Pharm 2018 Jun 19;544(1):181-190. Epub 2018 Apr 19.

Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital and MC Slotervaart, Louwesweg 6, 1066 EC Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijpharm.2018.04.037DOI Listing
June 2018

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial.

Clin Pharmacokinet 2018 05;57(5):637-644

Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40262-017-0582-9
Publisher Site
http://dx.doi.org/10.1007/s40262-017-0582-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904242PMC
May 2018

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

J Clin Oncol 2018 05 5;36(13):1291-1299. Epub 2018 Feb 5.

Dejan Juric, Massachusetts General Hospital Cancer Center, Boston; Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; Jordi Rodon and Josep Tabernero, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona; Marta Gil-Martin, Catalan Institute of Oncology - Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Filip Janku, The University of Texas MD Anderson Cancer Center, Houston, TX; Howard A. Burris, Sarah Cannon Research Institute and Tennessee Oncology; Jordan Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, the Netherlands; Mark R. Middleton, National Institute for Health Research, Oxford Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom; Martin Schuler, West German Cancer Center, University Duisburg-Essen, and German Cancer Consortium, Partner Site University Hospital Essen, Essen; Ruth Seggewiss-Bernhardt, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany; Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Douglas Bootle, David Demanse, Lars Blumenstein, and Cornelia Quadt, Novartis Pharma AG, Basel, Switzerland; Christina Coughlin, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.72.7107
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.72.7107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920739PMC
May 2018

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.

Cell 2018 05 10;173(6):1413-1425.e14. Epub 2018 May 10.

Division of Molecular Carcinogenesis, Oncode Institute, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00928674183050
Publisher Site
http://dx.doi.org/10.1016/j.cell.2018.04.012DOI Listing
May 2018

PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.

Clin Pharmacokinet 2018 04;57(4):427-437

Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40262-017-0587-4DOI Listing
April 2018

Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS.

Ther Drug Monit 2018 04;40(2):230-236

Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0000000000000479DOI Listing
April 2018

Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry.

J Chromatogr B Analyt Technol Biomed Life Sci 2018 Apr 9;1083:204-208. Epub 2018 Mar 9.

Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands; Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Chemical Biology & Drug Development, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jchromb.2018.03.014DOI Listing
April 2018

Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials.

Radiother Oncol 2018 03 14;126(3):443-449. Epub 2017 Nov 14.

Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Biological Stress Response, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2017.10.017DOI Listing
March 2018

EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid.

J Neurooncol 2018 Mar 30;137(1):1-10. Epub 2017 Nov 30.

Department of Neuro-oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11060-017-2691-6
Publisher Site
http://dx.doi.org/10.1007/s11060-017-2691-6DOI Listing
March 2018

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.

Clin Pharmacokinet 2018 02;57(2):151-176

Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek Hospital/MC Slotervaart, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40262-017-0570-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784002PMC
February 2018

Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.

Int J Cancer 2018 01 30;142(2):424-430. Epub 2017 Sep 30.

Laboratory Genetic Metabolic Diseases, Departments of Clinical Chemistry and Clinical Genetics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.31065DOI Listing
January 2018

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

J Clin Oncol 2018 01 26;36(1):7-13. Epub 2017 Oct 26.

Vivek Subbiah and Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert J. Kreitman, National Institutes of Health, Bethesda, MD; Zev A. Wainberg, University of California Los Angeles, Los Angeles, CA; Jae Yong Cho, Yonsei University College of Medicine Gangnam Severance Hospital; Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht Institute for Pharmaceutical Sciences, Utrecht, the Netherlands; Jean Charles Soria, Institut Gustave Roussy, University of Paris-Sud, and University of Paris-Saclay, Villejuif, France; Patrick Y. Wen, Dana-Farber Cancer Institute, Boston, MA; Christoph Zielinski, Comprehensive Cancer Center, Medical University Vienna; Vienna, Austria; and Gladys Urbanowitz, Bijoyesh Mookerjee, Dazhe Wang, and Fatima Rangwala, Novartis Oncology, East Hanover, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.6785DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791845PMC
January 2018

Enrichment of Circulating Endothelial Cells by CD34 Microbeads Followed by Enumeration Using Flow Cytometry.

Thromb Haemost 2017 12 6;117(12):2356-2368. Epub 2017 Dec 6.

Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1160/TH17-04-0254DOI Listing
December 2017

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.

Clin Pharmacol Ther 2017 Nov 7;102(5):765-776. Epub 2017 Sep 7.

Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.787DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656880PMC
November 2017

Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium.

Eur J Cancer 2017 11 9;85:78-85. Epub 2017 Sep 9.

Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek-The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; Division of Clinical Pharmacy, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.07.050DOI Listing
November 2017

An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma.

J Chromatogr B Analyt Technol Biomed Life Sci 2017 Nov 16;1068-1069:119-124. Epub 2017 Oct 16.

Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; Division of pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jchromb.2017.10.033DOI Listing
November 2017

Fixed Dosing of Monoclonal Antibodies in Oncology.

Oncologist 2017 10 28;22(10):1212-1221. Epub 2017 Jul 28.

Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/lookup/doi/10.1634/th
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2017-0167DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634778PMC
October 2017

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing.

Clin Pharmacokinet 2017 09;56(9):987-997

Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40262-017-0510-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563343PMC
September 2017

High-Tech Drugs in Creaky Formulations.

Pharm Res 2017 Sep 30;34(9):1751-1753. Epub 2017 May 30.

The Netherlands Cancer Institute and the Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11095-017-2185-4DOI Listing
September 2017

Pharmacogenetic analysis of irreversible severe cisplatin-induced nephropathy: a case report of a 27-year-old woman.

Br J Clin Pharmacol 2017 Sep 31;83(9):2120-2122. Epub 2017 May 31.

Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.13309DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555872PMC
September 2017

Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction.

J Chromatogr B Analyt Technol Biomed Life Sci 2017 Sep 23;1061-1062:300-305. Epub 2017 Jul 23.

Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands; Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Chemical Biology & Drug Development, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jchromb.2017.07.034DOI Listing
September 2017

Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer.

Clin Cancer Res 2017 Aug 25;23(16):4540-4544. Epub 2017 Apr 25.

Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-0520DOI Listing
August 2017

Improving the solubility of nilotinib through novel spray-dried solid dispersions.

Int J Pharm 2017 Aug 8;529(1-2):294-302. Epub 2017 Jul 8.

Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital and MC Slotervaart, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03785173173060
Publisher Site
http://dx.doi.org/10.1016/j.ijpharm.2017.07.010DOI Listing
August 2017

AKT Inhibition in Solid Tumors With AKT1 Mutations.

J Clin Oncol 2017 Jul 10;35(20):2251-2259. Epub 2017 May 10.

David M. Hyman, Lillian M. Smyth, Mark T.A. Donoghue, Matthew T. Chang, Jonathan B. Reichel, Nancy Bouvier, S. Duygu Selcuklu, Tara E. Soumerai, Jean Torrisi, Joseph P. Erinjeri, Michael F. Berger, Sarat Chandarlapaty, David B. Solit, José Baselga, and Barry S. Taylor, Memorial Sloan Kettering Cancer Center; David B. Solit, Weill Cornell Medical College, Cornell University, New York, NY; J. Carl Barrett and Brian Dougherty, AstraZeneca, Waltham, MA; Helen Ambrose, Andrew Foxley, Justin P.O. Lindemann, Robert McEwen, Martin Pass, and Gaia Schiavon, AstraZeneca, Cambridge; Emma J. Dean, The Christie National Health Service Foundation, Manchester; Udai Banerji, Royal Marsden Hospital, London, United Kingdom; Shannon N. Westin, The University of Texas MD Anderson Cancer Center, Houston, TX; Philippe L. Bedard, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Hideaki Bando, National Cancer Center East Hospital, Kashiwa, Japan; Anthony B. El-Khoueiry, University of Southern California Norris Comprehensive Cancer Center; Alain Mita, Cedars-Sinai Medical Center, Los Angeles, CA; José A. Pérez-Fidalgo, Hospital Clinico de Valencia, Valencia, Spain; and Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.0143DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501365PMC
July 2017

Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies.

Oncologist 2017 07 2;22(7):864-872. Epub 2017 Jun 2.

Department of Clinical Pharmacology, Amsterdam, The Netherlands

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2017-0031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507642PMC
July 2017

Fast and Adequate Liquid Chromatography-Tandem Mass Spectrometric Determination of Z-endoxifen Serum Levels for Therapeutic Drug Monitoring.

Ther Drug Monit 2017 04;39(2):132-137

*Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek and MC Slotervaart, Amsterdam; †Division of Pharmacoepidemiology and Clinical Pharmacology, Science Faculty, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht; and ‡Department of Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0000000000000372DOI Listing
April 2017

Clinical Trials Series — Large Pharma.

N Engl J Med 2017 04;376(14):e28

Netherlands Cancer Institute, Amsterdam, the Netherlands

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1701621DOI Listing
April 2017

Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients.

Clin Pharmacokinet 2017 03;56(3):293-303

Department of Pharmacy and Pharmacology, Netherlands Cancer Institute-Antoni van Leeuwenhoek and MC Slotervaart, Louwesweg 6, PO Box 90440, 1006 BK, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40262-016-0443-yDOI Listing
March 2017

Potential Benefit of Low-Dose Candesartan in Trastuzumab-Induced Cardiotoxic Effect-Reply.

JAMA Oncol 2017 Feb;3(2):279-280

Division of Medical Oncology, Department of Clinical Pharmacology, NKI, Amsterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.3595DOI Listing
February 2017

Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar.

Drug Deliv Transl Res 2017 02;7(1):125-131

Department of Clinical Pharmacology, Antoni van Leeuwenhoek-The Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13346-016-0346-3DOI Listing
February 2017

How Much Longer Will We Put Up With $100,000 Cancer Drugs?

Cell 2017 02;168(4):579-583

Division of Molecular Carcinogenesis and Cancer Genomics Centre Netherlands, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2017.01.034DOI Listing
February 2017

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

J Clin Oncol 2017 Jan 21;35(2):157-165. Epub 2016 Nov 21.

Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.2048DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865065PMC
January 2017

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients.

Clin Cancer Res 2016 Dec 28;22(23):5738-5746. Epub 2016 Jul 28.

Department of Medical Oncology, UMC Utrecht Cancer Center, University Medical Center Utrecht, Utrecht, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-1255DOI Listing
December 2016

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.

J Clin Oncol 2016 12 31;34(36):4371-4380. Epub 2016 Oct 31.

Suzanne Leijen, Robin M.J.M. van Geel, and Jan H.M. Schellens, The Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands; Anna C. Pavlick, New York University Medical Center, New York, NY; Lee Rosen, University of California Los Angeles, Santa Monica, CA; Raymond Lam, Shelonitda Rose, Mark A. Lee, Tomoko Freshwater, and Stuart Shumway, Merck, Kenilworth, NJ; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Albiruni R. Abdul Razak and Amit M. Oza, Princess Margaret Hospital, Toronto, Ontario, Canada; Raoul Tibes, University Hospital of Würzburg, Würzburg; Tim Demuth, Sandoz AG, Holzkirchen, Germany; and Li Wen Liang, Merck Sharp & Dohme R&D, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.5991DOI Listing
December 2016

Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.

Ther Drug Monit 2016 12;38(6):649-656

*Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital and MC Slotervaart, Louwesweg, Amsterdam, The Netherlands; and †Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0000000000000349DOI Listing
December 2016

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.

J Clin Oncol 2016 12 28;34(36):4354-4361. Epub 2016 Oct 28.

Suzanne Leijen, Robin M.J.M. van Geel, Gabe S. Sonke, Daphne de Jong, Efraim H. Rosenberg, Serena Marchetti, Dick Pluim, Erik van Werkhoven, Jos H. Beijnen, and Jan H.M. Schellens, The Netherlands Cancer Institute, Amsterdam; Jos H. Beijnen and Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands; and Shelonitda Rose, Mark A. Lee, and Tomoko Freshwater, Merck, Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.5942DOI Listing
December 2016

Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?

Cancer Treat Rev 2016 Nov 13;50:23-34. Epub 2016 Aug 13.

Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Faculty of Science, Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.08.002DOI Listing
November 2016

Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.

Cancer Chemother Pharmacol 2016 10 20;78(4):875-80. Epub 2016 Aug 20.

Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-3137-0DOI Listing
October 2016

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma.

J Chromatogr B Analyt Technol Biomed Life Sci 2016 Oct 11;1033-1034:390-398. Epub 2016 Sep 11.

Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands; MC Slotervaart, Department of Pharmacy & Pharmacology, Louwesweg 6, 1066 EC Amsterdam, The Netherlands; The Netherlands Cancer Institute, Department of Clinical Pharmacology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jchromb.2016.09.012DOI Listing
October 2016

Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel.

Int J Pharm 2016 Sep 29;511(2):765-73. Epub 2016 Jul 29.

Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek Hospital/MC Slotervaart, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijpharm.2016.07.068DOI Listing
September 2016

Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar.

J Pharm Anal 2016 Aug 23;6(4):268-275. Epub 2016 Apr 23.

Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpha.2016.04.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762608PMC
August 2016